COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE

Similar documents
4th EUROPEAN COLORECTAL CANCER DAYS

Additional Information to the Press Release

Lessons learnt from cancer screening programmes as an example for establishing the Czech National Coordination Centre

Efficacy, effectiveness, quality: sources of data

3rd EUROPEAN COLORECTAL CANCER DAYS: BRNO 2014 PREVENTION AND SCREENING

Measuring performance and quality indicators of CRC screening

COMMISSION OF THE EUROPEAN COMMUNITIES

COUNCIL RECOMMENDATION of 2 December 2003 on cancer screening (2003/878/EC)

Czech CRC screening program at the point of switch to the population based design

Monitoring of equity in access to CRC screening and CRC care: two sides of the same coin

Colon cancer screening : age 50 or over I'll talk to my doctor about it

Practical challenges in establishing and running the Czech national colorectal cancer screening programme

Cancer Screening Program in GEORGIA

Bowel Cancer Prevention and Screening. Harriet Wynne, Cancer Council Victoria

Bowel cancer screening and prevention

Overview of radiation oncology in the Czech Republic

Efforts in Fighting against Cancer in Croatia Have to be Focused on the Primary Health Care

Best practices in collecting and processing data in CRC screening and after it

GENERAL PRACTITIONERS IN THE 1ST LINE OF CANCER PREVENTION

Colorectal Cancer & Screening 1 st Men s Health Conference

European Cancer Network Aims and Activities

Workshop Report. Follow-up care / post-acute care / aftercare, long-term and palliative care

2. CANCER AND CANCER SCREENING

Together Until the End

UPDATE REPORT: POPULATION SCREENING PROGRAMMES IN POWYS. This is a briefing report on the delivery of population screening in Powys

Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2015

European Partnership for Screening

EuropaColon Uniting citizens in the fight against colorectal cancer. Zorana Maravic Director of Group Development May, 2013

EUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF ESTONIA

Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2017

Implementing Breast Cancer Survivorship National Cancer Centre Singapore

Breast Care Nursing Team

Primary care at the forefront of colorectal cancer screening

Cancer Prevention and Treatment

Colorectal cancer screening

Can epidemiological data contribute to improvement in cancer care?

Honouring the First Nations Path of Well-being

CRC screening from the viewpoint of its clients and patients results of survey

A microsimulation study of the benefits and costs of screening for colorectal cancer Christopher Eric Stevenson

7.14 Young Person and Adult (YPA) Screening Programmes

Cervical cancer screening in Norway

NHS Bowel Cancer Screening Programme

COLORECTAL CANCER. Colorectal Cancer (CRC) 3 rd most common cancer in U.S. 3 rd deadliest cancer in U.S. 12/4/2014

NHS Bowel Cancer Screening Programme

Annual Report. Public Health Screening Programmes TO 31 MARCH Extract: Chapter 3 : Planning for Bowel Screening Programme

NHS KINGSTON. Contents

Implementing of Population-based FOBT Screening

EuropaColon Expands into Digestive Cancers Europe. Our objective is to save an additional 250,000 Europeans every year

What is cancer? A group of 100 different diseases. The uncontrolled, abnormal growth of cells. Cancer may spread to other parts of the body.

SCREENING. Highlights. Introduction HEALTH STATUS REPORT CHAPTER 9: SEPTEMBER 2016

NICaN workshop: Colorectal Cancer Follow-up

National Screening Programmes (Adult Population) Annual Report

COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.

The Spanish Society of Medical Oncology: objectives, structure and history

Blue Star Sunday. Increasing Awareness About Colon Cancer. Dear Faith Community,

Bowel cancer Screening Programme

Unfortunately you re not. So talk to your health care provider about screening today.

Cancer in Halton. Halton Region Cancer Incidence and Mortality Report

National Programme for Breast Cancer Screening. Invitation

Information for families with a slightly increased risk of bowel cancer. Family History of Bowel Cancer

PDF // POSITIVE COLON CANCER RESULTS

How Italy and France take on rare sarcoma cancers

Integration of palliative care into oncology

Breast cancer screening programme: France. Dr. Rosemary Ancelle-Park Department of health Office for chronic diseases

An Introduction to MUTYH Associated Polyposis (MAP)

2017 CANCER ANNUAL REPORT

ANNEX 07 - LATVIA MEDIA GUIDE on CERVICAL CANCER IN LATVIA

Breast Cancer Screening Factsheet

2012 update. Bowel Cancer. Information for people at increased risk of bowel cancer. Published by the New Zealand Guidelines Group

State of the Art of Rare Disease Activities in EU Member States and Other European Countries. Slovak Republic Report

Cancer Screening Programmes BOWEL CANCER SCREENING. The Facts

State of Wyoming. Department of Health

th Medical Group Report Card

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)

LET S TALK ABOUT CANCER

JU Welcome Centre for International Guests

Programme September 2017 Prague, Czech Republic

Standard Summary Project Fiche IPA centralised programmes

INTERACTION WITH SCREENEES AND PATIENT ORGANIZATIONS

European Commission Initiative on Breast Cancer. Annual Declaration of Interests (ADoI)

2016 Cancer Program Outcomes Report

RESULTS OF BREAST AND CERVICAL CANCERS SCREENING IN HAIPHONG WITHIN 5 YEARS FROM 2011 TO Hoa Nguyen Lam, Huyen Suong Ho Thi et al.

Breast Density It's the Law

12: BOWEL CANCER IN FAMILIES

Is cancer a chronic disease? Prof. Dace Baltina Riga East University Hospital Ministry of Health

Guidelines for Breast, Cervical and Colorectal Cancer Screening

California Colon Cancer Control Program (CCCCP)

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Northern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013

Quick Reference Guide CAT4. Cancer Screening

Prostate cancer was the most commonly diagnosed type of cancer among Peel and Ontario male seniors in 2002.

Clinical CRC registries of the Czech Society for Oncology

Implementation of Faecal Immunochemical Testing as the screening test for Bowel Screening. Programme in Wales

Annual Report with statistical data from Bermuda National Tumour Registry. Bermuda Hospitals Board Office of the Chief of Staff, KEMH

Bowel cancer screening the facts. Bowel cancer screening: the facts

Aneurin Bevan Health Board. Screening Programmes

Bowel Cancer Information Leaflet THE DIGESTIVE SYSTEM

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013

Statistics at a glance

Transcription:

COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE Brno, 29 May 2015: For the fourth time in a row, the second largest city of the Czech Republic will host the European Colorectal Cancer Days, an international conference dedicated to the issue of colorectal cancer. The tradition of this event, which was started four years ago by Dr Pavel Poc, a Member of the European Parliament, and by Dr Ladislav Dusek, Director of the Institute of Biostatistics and Analyses of the Masaryk University, will again attract a wide spectrum of visitors from many European countries, and from across various groups involved in the fight against colorectal cancer. The main topics of the programme will include a healthy lifestyle, evaluation of the recently introduced personalised invitations of Czech citizens to cancer programmes, as well as the issue of availability of a high- quality care provided to patients diagnosed with cancer. The Czech Republic is one of the countries with the highest burden of cancer: each year, more than 77,000 people are diagnosed with cancer, and almost 28,000 patients die of cancer in this country. The prevalence of cancer patients has been rising steadily, besides other things as a result of ageing of the Czech population. At the end of 2013, there were more than 450,000 citizens living in the Czech Republic who had received a diagnosis of cancer. These alarming numbers themselves justify the need of effective cancer prevention, and of planning the costs of cancer care. More than 8,000 Czech men and women are diagnosed with colorectal cancer each year; unfortunately, the disease is still very often diagnosed at advanced stages (Table 1). The high treatment burden places heavy demands on the organisation of cancer care. Before treatment initiation, each patient should be assessed by a multidisciplinary team of specialists, who would evaluate the patient s condition, and would determine an optimum treatment. Patients diagnosed at advanced stages of cancer should be treated in Comprehensive Cancer Centres. A list of centres concentrating the highly specialised treatment, as well as the advice on how to make an appointment, is available at www.linkos.cz the official website of the Czech Society for Oncology (most of the patient information is available in the Czech language only). Among the organised programmes in the Czech Republic, colorectal cancer has had the lowest participation rate so far. Over half a million men and women undergo the faecal occult blood test (FOBT) each year. During the subsequent colonoscopy, adenoma (a non- malignant tumour which might develop into colorectal cancer if not detected) is removed in more than 10,000 individuals. Moreover, approximately 900 cases of colorectal cancer are detected each year by

; however, the chance of cure is very good if the tumour is detected at an early stage. Despite these good prospects, however, a large proportion of Czech men and women still does not participate in cancer programmes, missing the opportunity of avoiding cancer, or at least reducing its consequences significantly. For this reason, a project of personalised invitations of Czech citizens to cancer programmes was launched in January 2014, aiming to increase the participation rate in these preventive. Invitations are sent to those citizens who have not participated in the respective yet. The project was prepared by the Czech Ministry of Health in cooperation with expert medical societies and health insurance companies. Health insurance companies themselves invite their clients to. In 2014, almost 2 million Czech citizens were invited to participate in programmes. More than 1.5 million persons were invited to colorectal cancer alone, and almost 15% of those invited actually responded (by undergoing FOBT or colonoscopy). According to preliminary data, adenomatous polyps were detected in more than 4,000 patients; an easy treatment of polyps means a complete cure for such patients. Supplements to this press release summarise the results of personalised invitations during the first 12 months of the project (Tables 2 and 3). In cooperation with the Czech Ministry of Health, the evaluation was performed by the Institute of Biostatistics and Analyses of the Masaryk University, based on data provided by health insurance companies. Even an optimally functioning, however, cannot provide much help to patients who were diagnosed with cancer in the past. In the Czech Republic, there are more than 50,000 patients who have had colorectal cancer in their medical history. Standardised, high- quality and available care of these patients is another challenge for the Czech health care system. Analysed data have shown large differences in the availability of modern treatment among individual regions of the Czech Republic, particularly in the treatment of advanced stages of CRC. Inadequate centralisation of surgical treatment poses yet another problem: very complicated cases are often operated on in health care facilities which only deal with less than 15 such procedures annually. Improvements of this situation, as well as strengthening of the standard approach towards all patients, are among the biggest challenges for this segment of medicine in the Czech Republic. Organization of the conference: Pavel Poc, Member of the European Parliament; Institute of Biostatistics and Analyses, Masaryk University, Brno (www.iba.muni.cz); Institute of Health Information and Statistics of the Czech Republic (www.uzis.cz). Detailed information about the conference is available at www.crcprevention.eu.

Table 1. Basic characteristics of colorectal cancer patients in the Czech Republic in the period 2008 2012 1 Parameter Incidence rates (numbers of new cases) Number of new cases (per 100,000 population per year) Absolute number of new cases (per year) Proportion of all newly diagnosed cancers Trend in the period 2002 2012 Typical age of patients (25th 75th percentile) Sex Value divided according to sex Men: 93.6 Women: 61.3 Men: 4,820 Women: 3,275 Men: 11.9 % Women: 9.2 % Men: +2.5 % Women: - 2.1 % Men: 61-76 years Women: 62-79 years Occurrence men : women 1.5 : 1 Overall value for both sexes 77.2 8,095 10.6 % +0.8 % 62-77 years Mortality rates (numbers of deaths) 2 Number of deaths (per 100,000 population per year) Absolute number of deaths (per year) Men: 42.6 Women: 29.1 Men: 2,191 Women: 1,552 Trend in the period 2002 2012-17.8 % Proportion in the overall mortality Prevalence rates (patients still alive) Number of persons with cancer in their medical history (per 100,000 population; as on 31 Dec 2012) Absolute number of persons with cancer in their medical history (as on 31 Dec 2012) Trend in the period 2002 2012 Men: 4.1 % Women: 2.9 % Men: 576.2 Women: 433.0 Men: 29,736 Women: 23,158 Men: +61.3 % Women: + 8.2 % 35.7 3,743 3.5 % 503.3 52,894 +55.3 % 1 The overall epidemiological burden; data involves all records on respective cancers, including those detected as subsequent primary tumours in the same person. Source of data: Czech National Cancer Registry 2 Source of data: Czech Statistical Office Incidence = Number of newly diagnosed cancers per one year. It can be expressed as an absolute number of cases per year or as a rate per 100,000 persons (men or women) per year. Mortality = Number of deaths from a given cancer per one year. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons (men or women) per year. Prevalence = the number of people who had received a diagnosis of a given cancer and who were alive on the 31 December 2012. It can be expressed as an absolute number or as a rate per 100,000 persons (men or women).

Results of the project of personalised invitations Table 2. Numbers of insured persons invited to individual cancer programmes during 2014 (invitations sent to a total of 1,959,504* persons). Variant of invitation letter Men invited to participate in colorectal cancer in cervical cancer in breast cancer in cervical and breast cancer in colorectal cancer in cervical and colorectal cancer in breast and colorectal cancer in all cancer programmes Total number of insured persons invited to cancer programmes cervical cancer 217,484 Invitation to participate in breast cancer 126,962 114,161 114,161 colorectal cancer 783,151 391,152 46,530 46,530 61,853 61,853 218,211 218,211 218,211 596,386 521,187 1,500,897 * The total number of invited persons does not correspond to the sum of numbers of invited persons to individual programmes, because many insured persons are invited to multiple programmes at the same time.

Table 3. Results of cancer programmes before the start of personalised invitations, and modelled results after the start of personalised invitations, all age groups. Monitored period of organised Cervical cancer (C53) Breast cancer (C50) Colorectal cancer (C18 C20) 2010 2013 2002 2013 2006 2013 Total number of performed Number of patients with a positive result of examination* 8,411,969 cytology 19,405 patients with a cytological finding of precancerous lesion or carcinoma 4,863,628 mammography 24,994 patients with a finding of breast cancer * In the vast majority of these findings, there is a high chance of a complete cure. Number of people coming as a result of personalised invitations (2014 preliminary data) Number of patients with a positive result of examination as a result of personalised invitations (2014 preliminary data)* 55,393 cytology 105 patients with a cytological finding of precancerous lesion or carcinoma 70,082 mammography 332 patients with a finding of breast cancer * In the vast majority of these findings, there is a high chance of a complete cure. 3,559,558 FOBT 19,798 PSC 44,378 patients with a finding of adenoma 5,066 patients with a finding of carcinoma 217,214 FOBT or PSC 4,170 patients with a finding of adenoma 165 patients with a finding of carcinoma Abbreviations: FOBT = faecal occult blood test; PSC = primary colonoscopy Source of data: Institute of Biostatistics and Analyses of the Masaryk University (cancer programmes), Czech National Reference Centre, health care payers